{"name":"Sight Sciences, Inc.","slug":"sight-sciences-inc","ticker":"","exchange":"","domain":"","description":"Sight Sciences, Inc. is a medical technology company focused on developing and commercializing innovative solutions for ophthalmic disorders, particularly in the areas of glaucoma and dry eye disease. The company has two marketed products and is actively engaged in clinical research to expand its portfolio.","hq":"","founded":0,"employees":"~100","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.5B","metrics":{"revenue":77363000,"revenueGrowth":-3.1,"grossMargin":86.2,"rdSpend":14606000,"netIncome":-38426000,"cash":91965000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Latanoprost plus adjunctive glaucoma medication","genericName":"Latanoprost plus adjunctive glaucoma medication","slug":"latanoprost-plus-adjunctive-glaucoma-medication","indication":"Open-angle glaucoma","status":"marketed"}]}],"pipeline":[{"name":"Latanoprost plus adjunctive glaucoma medication","genericName":"Latanoprost plus adjunctive glaucoma medication","slug":"latanoprost-plus-adjunctive-glaucoma-medication","phase":"marketed","mechanism":"Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOS292TlBzMXlRbEhISldheWJzMThicTdnbndTT0ZyUzlHeV95UjVRZV9hOFdYbFNHMTlKaHVOUFdWbTB4ZWtaYy02cmNaN2xNZGtpLWRzMXhmcWhPMDhTMlgwUlhFYUZjM29JYVJ2VkhvWnkzUFBtRWc3Q3pONzdPNnNoTTllbVc0cHVXMUYzLTk4MmNEa1VzWkJuQ3VpMVQ2VFUydHZwSHZUb1FiY2RCekZR?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"[Form 4] Sight Sciences, Inc. Insider Trading Activity - Stock Titan","headline":"[Form 4] Sight Sciences, Inc. Insider Trading Activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxORjJBdXctdXhiS0gwTEZjX1N1NUpEdjJxaE5xTmE4aFN6VDY0eWQ2NlhrSWt6cXk4VHdpTTZQeEg4c0o3c0h2dGlqWV81YXNKWF9Zdks0aWRUWVI0TS1sWGdaM1BpNkI1c09YZTlKQTM2alluWmJ3Y2I4NG16eWJ6MGFWeUl4ZjNPY0RUc2xBbV9qek9SdERrZ3M4S0YyS3NaQjZGTUF6VU5BWHllYmZaS0ln?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed - Stock Titan","headline":"Sight Sciences (SGHT) CTO tax-related sale of 8,168 shares disclosed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNVTJJX29uU2tNUVFDWDFPNGxPSU5GdDhQbzBjeU1FVUllQmhrOXFTd2xtMWhJaXJ5VWVLWFhaUWJFVnFubXhVLXhaQjRxTmRlMm93cVZmMmpFOXZmZWwtMGp2QlZOMXNPUEkxZi0tQUlkZkJES2dTS29NQTZXSVBodENqSXpnVXFXeW93bTlocGFHZ256MVNMeTlQRjR5a0RoeVpyczZuYVI3XzJvV2stR3J3?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations - Stock Titan","headline":"Sight Sciences (SGHT) EVP Brenton sells 2,869 shares for RSU tax obligations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxQS3R5NjVPTzVFeFhzZU4xa0FlcFB1ZVJGcUhlWFlXRFAtZmR6SVkxWGVfY0FvVjJsSGhCN0p3NHE5aTR6aDVxeDA3MlVpcGhRZWRKT1pITER4WHhzcTBmSVlJN2VNYzlndE94bWRjcUVDaW5QNnByeWpWVnpKSXp0Zm01UkJDallSMWtLdG4wOTZfQlNaUnNMQTNyNzU1akgtQ09jYktIWktWaFVKVDJxVTJNTk9fZ2FxbWJYWlJSX3RyUXlyZ3ZwTUtpcmtpS2tCUHBKMGl4MmFya2hxM2NxMjBlLVpjNHk1d25CT1J2TzhNeVpQVmQxMGpGaEdxcUZ6NzBZd3JMQk1rcVRWbjFKa0R3czBDNnExUUVrdG1xODR5WGxkVHZaRXVVTjBlZ0RkaHpkTUY2LVFtbjEzZzRTeG9ob1dKb3NpSFRlYlpzc0ZxQzhNWTBfa1h5enU4anc?oc=5","date":"2026-03-30","type":"trial","source":"GlobeNewswire","summary":"Sight Sciences Secures Order on Post-Trial Motions That - GlobeNewswire","headline":"Sight Sciences Secures Order on Post-Trial Motions That","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNbG14YXBxYkpkX0RfQVZCUTE4eFlYb3dnbU5qenpoOVlvODdFRi1Idkh5MHBYZHpsOHUxZTNSMU0zNXdfelB0UllUU2VSMF85ME5Ld2JtRWoyY1BsLVd4bXR6b1NwdTlMeGpINlBQaUltUnhHUDViV2gtSVBfTGk0QjU0S1dEQ2VIOW1xYk1peDc3SXJWQW5DLW9GWHF6UDZpc0hnTHYzU3IzUlNnTUUwbGhvU3BHV1J3UHc?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Eyecare tech company Sight Sciences to webcast Apr. 13 fireside chat - Stock Titan","headline":"Eyecare tech company Sight Sciences to webcast Apr. 13 fireside chat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYm83QjVENGJLR0dWYXNXcVRWbmF5T25QUjFsb0pxM2VOR050ZmdNWnZ3T1dMQ3pXam9XUjhOZTN2QndscHNfSklkV3lLRkZZdW9yR25vT05GMHJpb3J5eG44eDl0UHBWTzFUcUdFb25RcGlnQXdHbGYySkdLSTlsZkZIUUNYZnVvdEE4b1FrdnNyOEp5c0tvOUR5Z1YyOFE2Xzk1VjNCQjB3U0U?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties - Stock Titan","headline":"Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTnRNMy1LazFIUFZScFNFRzM0dmRwekxKcFR4bmt6R2dyTGtMTkhCU3d2MlBUbDJZVFNKSG9HVTZBU1pwUFhCc3E2amN5TFpQeG5RTmV0cy1NUFlmTm1EMjRBdHNubjQta3BiV2R4ZmUwbTVNV1V2OE1vR0dDZi16V3FQT1ppOU9pRC1ITkVQdFpGV21YbDJ6akJhbHU3Q1VnMFVJQTRyOTVVUQ?oc=5","date":"2026-03-06","type":"earnings","source":"Insider Monkey","summary":"Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript - Insider Monkey","headline":"Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQemxjQU1oY3lyS2hVSW5XM09jcjhEWWlXQ0FGdjNCWTJObnFRQ1FwbGNQYUNIUXpWVTNnNl9MZTNqRGlzOXhIT2NCeC1OQWpMMVMybDZSOVBVekZEZzhHS2NuTmMxV2dETWpBRVczQUsweng5VGRTOWRKNFZ4eWJwVGcyM0dMWEhCR1RzVUZjRzkzUEN6c1p1MTQ1M29aWEY1cl9MekN2NWw4S3FvSlVURHVyV3I?oc=5","date":"2026-03-05","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Can Fite Biopharma (AMEX:CANF), Gossamer Bi - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session - Can Fite Biopharma (AMEX:CANF), Gossamer Bi","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNcEFIR3ZfWmtvTjhGa0NTOGQ5STZPOUVWbmY2QmlzRk5id05wZVVDMl9janlHa0FuSjVwZlZrc1d1XzdxMXU0ZVFRQ1hNM20teEdUaHFobGNVd2lRcUx3T2REekMzX2hDcnNpNGtJeVZ2c29YRkgzRWZucWVHeVNCV3FIXzlULUx4MTRsbkd6aGJ2RDhzRXVXdjNJZWt5SHVGYnROZml4ejRVdjVYd2NJQVQ4YkRRYlpqTTZWVmdnRjNic2pE?oc=5","date":"2026-03-02","type":"pipeline","source":"Investing.com","summary":"Stifel raises Sight Sciences stock price target on TearCare survey - Investing.com","headline":"Stifel raises Sight Sciences stock price target on TearCare survey","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQR2RDUlZoLXdGNGJ0UF83aU1ua1REVzVJdHc4SVYydGhwelU3YzU5M25vZmcwR2lKX2tXekphbGRuX1ZDcjRJVGJVNEttZUtkVVVQRHVxN1YyMUtfQkNYN2g2SmVNT0hJV2ZfQlV6aV9NeUs1ODI4Ml9oVkhxT0RXdjBQaHUteV9aZk9DTE9wUmM4OE9VS0FpajE4UEgzR3ZXMjJBTmxR?oc=5","date":"2026-02-23","type":"pipeline","source":"Ophthalmology Times","summary":"Building a dry eye clinic around intense pulsed light treatment - Ophthalmology Times","headline":"Building a dry eye clinic around intense pulsed light treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNR2VKWTdWcWRYci1vV20tRzlFRnJ0VDlGaGd0NnFrdk43SFZTWXlUcWh3WFIxN19EaTk1WGRLYVNpQzZ1UF81Zl9qVDdhVTJaNWg4LTVVbDB3dDY3QTM3QjlyS3VNSE10UjBwMk51Y1NfelRDLWNKRVBWU0pIdXdraUhHTXRMZWNRMWlrbER2RlF2NFk0Nms0SDRacWRKRXAtenhNbQ?oc=5","date":"2025-08-28","type":"pipeline","source":"Seeking Alpha","summary":"Sight Sciences Trying To Thread An Increasingly Narrow Needle (NASDAQ:SGHT) - Seeking Alpha","headline":"Sight Sciences Trying To Thread An Increasingly Narrow Needle (NASDAQ:SGHT)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":77363000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":77363000,"period":"2025-12-31"},{"value":79866000,"period":"2024-12-31"},{"value":81056000,"period":"2023-12-31"},{"value":71331000,"period":"2022-12-31"},{"value":48956000,"period":"2021-12-31"},{"value":27640000,"period":"2020-12-31"}],"grossProfit":66666000,"grossProfitHistory":[],"rdSpend":14606000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-38426000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":91965000,"cashHistory":[],"totalAssets":115300000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}